Not provided
Not provided
Not provided
Not provided
Study currently suspended due to device-related issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Interventional, prospective, randomized, controlled, double blind, parallel groups, nonprofit, single center trial
The goal of this clinical trial is to compare, the efficacy of
in patients with Crohn's rectovaginal fistulas refractory to standard treatment,
Secondary objectives are improvement of the clinical outcome (clinical remission, clinical response, failure), time elapsed between surgery and clinical outcome, onset of any recurrences, safety and improvement in quality of life.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Microfractured adipose tissue injection and plug placement | Experimental | Liposuction (up to 100 cc of adipose tissue) Processing of adipose tissue with lipogems system Drainage of sepsis, courettage of fistula tract Placement of biological prosthesis in the fistula tract, suturing the mesh with interrupted PDS sutures at the internal sphincter Injection of 15 cc of microfractured adipose tissue into the submucosa around the internal orifice and along the fistula tract |
|
| endoanal mucosa flap | Active Comparator | A 6-0 absorbable suture will be placed on the skin at the level of the thigh to simulate liposuction Drainage of sepsis, courettage of fistula tract A U-shaped or vertical endoanal mucous flap will be made, after infiltration with 1:100,000 adrenaline of the mucosa surrounding the internal orifice, mobilization of the mucous flap, closure of the internal orifice at the muscular level with 2-0 absorbable stitches of PDS and suture of the mucosal flap with 3-0 absorbable vycril sutures. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Microfractured adipose tissue injection and plug placement | Device | surgery + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice and placement of a biological prosthesis |
| Measure | Description | Time Frame |
|---|---|---|
| combined remission | clinical (absence of gas and/or fecal and/or purulent vaginal drainage after gentle digital compression) and radiological (absence of abscesses > 3 mm) closure of the fistula | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| clinical remission | absence of gas and/or fecal and/or purulent vaginal drainage after gentle digital compression) with radiological presence of abscesses > 3 mm | 12, 16, 20, 24 weeks |
| clinical response |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients with recto-vaginal fistulas
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Silvio Laureti, MD | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna | BO | 40138 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012006 | Rectovaginal Fistula |
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D012003 | Rectal Fistula |
| D007412 | Intestinal Fistula |
| D016154 | Digestive System Fistula |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Randomization procedures and statistical analyses will be performed by an investigator not involved in the clinical evaluation or surgical treatment of patients. All clinical evaluations will be performed by independent co-investigators not involved in the surgical procedures and blinded to patient assignment. The dedicated radiologist who will evaluate the MRI scans will be blind to patient allocation. Surgeons will not be able to share information about the treatment used in the surgical procedure and will not be able to participate in any clinical evaluation of the MPC during the study.
|
at least 50% reduction in drainage of the treated vaginal orifice that was draining at baseline despite gentle digital compression.
| 12, 16, 20, 24 weeks |
| failure | "no change/worsening" of vaginal drainage and patients who, in the judgment of the investigator, require treatment with antibiotics to control recurrent perianal sepsis | 12, 16, 20, 24 weeks |
| IBDQ score (quality of life) | changes of Inflammatory Bowel Disease Questionnaire (IBDQ) scores | 4, 8, 12, 16, 20, 24 weeks |
| Incidence of adverse events | comparison of incidence of adverse events and serious adverse events in the two arms | 4, 8, 12, 16, 20, 24 weeks |
| D007410 |
| Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D012002 | Rectal Diseases |
| D014624 | Vaginal Fistula |
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D005402 | Fistula |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |